CHINA RES.DBLE.-CRANE PHARM.'A' sees a downgrade to Slightly Negative on account of less fundamental stars
The independent financial analyst theScreener just lowered the general evaluation of CHINA RES.DBLE.-CRANE PHARM.'A' (CN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date October 22, 2021, the closing price was CNY 11.62 and its target price was estimated at CNY 10.75.Beijing Double-Crane Pharmaceutical is engaged in the process and manufacture of raw material medicine, injection, tablet, capsule, granule, and pharmaceutical machinery equipment; the sale of self-developed products, mechanical and electrical equipment; and the provision of development and transfer of technology and related services. Through its subsidiaries, Co. is also engaged in the manufacture and sale of building decoration materials and cleaning products; the import and export of pharmaceutical products and machinery equipment; investment management; the manufacture and sale of beverage and health food; the installation of electro-mechanical equipment; and the maintenance of pipeline.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.